Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth ConferenceGlobeNewsWire • 08/07/24
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 08/03/24
Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024GlobeNewsWire • 07/30/24
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024GlobeNewsWire • 04/29/24
Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024GlobeNewsWire • 03/04/24
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational FlexibilityGlobeNewsWire • 01/18/24
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert ClaypooleGlobeNewsWire • 01/12/24
Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee OsteoarthritisGlobeNewsWire • 12/06/23
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial GuidanceGlobeNewsWire • 11/07/23
Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023GlobeNewsWire • 10/31/23